Clinical Trials Logo
  1. Home
  2. Gaucher's Disease
  3. NCT06193304

A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth — Acronym  

Gaucher's Disease Clinical Trial

Official title:
An Open-label Study to Assess the Absorption Through the Mouth After Three Repeated 50 mg Doses of Eliglustat Solution, Separated by 2-hour Intervals, Held in the Mouth for 30 Seconds With Swishing But Without Ingestion, in Healthy Subjects

Clinical Trial Summary

A study to assess the absorption of eliglustat through the mouth in healthy subjects and the safety of any systemic exposure resulting from oral surface absorption of eliglustat in healthy subjects.

Clinical Trial Description

Duration of the study for each subject, not including screening, will be 3 days including follow-up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06193304
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 1
Start date August 25, 2014
Completion date September 21, 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT00001289 - Effects of Enzyme Replacement in Gaucher's Disease N/A
Completed NCT00004488 - Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease Phase 2
Completed NCT00001410 - PEG-Glucocerebrosidase for the Treatment of Gaucher Disease Phase 1
Recruiting NCT00004293 - Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease Phase 2
Completed NCT00004294 - Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease Phase 1
Completed NCT04656600 - Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ Phase 4
Completed NCT01427517 - Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease Phase 1
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Completed NCT00001234 - Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells Phase 1
Completed NCT06188325 - A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers Phase 1
Completed NCT00001416 - Bone Response to Enzyme Replacement in Gaucher's Disease Phase 2
Active, not recruiting NCT00005900 - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT01586455 - Human Placental-Derived Stem Cell Transplantation Phase 1